abrdn Life Sciences Investors Shares of Beneficial Interest (HQL)
EBITDA Growth
242.48%
Quarterly · Period ending:
HQL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported242.48%period ending
Latest reported242.48%period ending
HQL Quarterly EBITDA YoY % (-30.35% → 242.48%)
Year-over-year change
High-resolution chart · PNG
HQL ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 242.481% | |
| 279.0769% | |
| -145.3303% | |
| 443.0915% | |
| 62.1804% | |
| 100% | |
| -176.9589% | |
| -322.2151% | |
| -62.8778% | |
| 9.5311% | |
| 100% | |
| 100% | |
| -200% | |
| 0% | |
| 100% | |
| -100% | |
| -100.0073% | |
| -99.7448% | |
| -99.9751% | |
| 26.1788% | |
| 195.0303% | |
| 267.7134% | |
| 267.7134% | |
| 423.4921% | |
| 423.4921% | |
| -105.2282% | |
| -105.2282% | |
| 19.2833% | |
| 19.2833% | |
| 3,869.403% | |
| 3,869.403% | |
| -102.9937% | |
| -102.9937% | |
| 525.1397% | |
| 525.1397% | |
| -81.4604% | |
| -81.4604% | |
| 1,632.5397% | |
| 1,632.5397% | |
| -29.8969% | |
| -29.8969% | |
| -111.5207% | |
| -111.5207% | |
| -30.353% | |
| -30.353% |